WASHINGTON (dpa-AFX) - ARIAD Pharmaceuticals, Inc. (ARIA) announced updated clinical results on its investigational tyrosine kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. The company said the study results show anti-tumor activity of AP26113 in patients with crizotinib-resistant anaplastic lymphoma kinase (ALK) positive NSCLC. AP26113 demonstrated activity against brain metastases in patients with prior crizotinib therapy, including responses of clinically meaningful duration.
With continued responses seen in the ongoing Phase 1/2 trial, ARIAD believes AP26113 has the potential to be a compelling new treatment option for patients with ALK-positive lung cancer.
A separate, pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic NSCLC who were previously treated with crizotinib is open and enrolling patients.
Copyright RTT News/dpa-AFX
© 2014 AFX News
